U.S. Digital Therapeutics Market Updates : to Propel at a CAGR of 19.2% from 2020 to 2027 ; 2MORROW, & Fitbit

Allied Market Research published a report, titled, "U.S. Digital Therapeutics Market by Application (Diabetes, Obesity, Cardiovascular Disease (CVD), Central Nervous System (CNS) Disease, Respiratory Disease, Smoking Cessation, Gastrointestinal Disorder (GID), and Others), Product (Software and Device), and Sales Channel (Business-to-Business(B2B), Business-to-Consumer (B2C)): Opportunity Analysis and Industry Forecast, 2020-2027." According to the report, the U.S. digital therapeutics industry generated $1.16 billion in 2019, and is estimated to generate $5.08 billion by 2027, growing at a CAGR of 19.2% from 2020 to 2027.

𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 https://www.alliedmarketresearch.com/request-sample/A06701

The growth of the U.S. digital therapeutics market is propelled by the increasing adoption of tablets, smartphones, and smart wearables, alongside healthcare apps. Additionally, there's a surge in the necessity to control healthcare expenses, and the uptake of technologically advanced healthcare products and applications further fuels this growth. However, market expansion is hindered by concerns regarding data privacy and inadequate reimbursement policies. Conversely, the market presents new prospects due to favorable laws and regulations supporting digital health technologies and an influx of investments from industry players.

In terms of application, the diabetes segment captured the largest market share in 2019, representing over one-fourth of the U.S. digital therapeutics market and is projected to sustain its leading position over the forecast period. This dominance is driven by the widespread prevalence of diabetes and the availability of cost-effective treatment solutions. Conversely, the obesity segment is anticipated to experience the most rapid Compound Annual Growth Rate (CAGR) of 22.1% from 2020 to 2027. This growth is fueled by the increasing number of overweight individuals and the convenient access to digital therapeutics software applications, aiding patients in maintaining healthy diets and monitoring physical activities.

In terms of product classification, the software segment constituted over two-thirds of the U.S. digital therapeutics market in 2019 and is expected to retain its revenue dominance through 2027. Additionally, this segment is anticipated to exhibit the highest Compound Annual Growth Rate (CAGR) of 20.3% during the forecast period. This growth can be attributed to the rising demand for cost-effective healthcare solutions and the development of innovative software and applications with advanced features aimed at promoting health and facilitating effective treatment. The research also examines the devices segment.

𝐒𝐩𝐞𝐚𝐤 𝐭𝐨 𝐎𝐮𝐫 𝐀𝐧𝐚𝐥𝐲𝐬𝐭- https://www.alliedmarketresearch.com/connect-to-analyst/A06701

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬 𝐅𝐨𝐫 𝐒𝐭𝐚𝐤𝐞𝐡𝐨𝐥𝐝𝐞𝐫𝐬
This report provides a detailed quantitative analysis of the current U.S. digital therapeutics market trends and forecast estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.

An in-depth market analysis includes analysis of various regions, which is anticipated to provide a detailed understanding of the current trends to enable stakeholders formulate country-specific plans.

A comprehensive analysis of factors that drive and restrain growth of the market is provided.

Country-wise market conditions are comprehensively analyzed in this report.
The projections in this report are made by analyzing the current trends and future market potential from 2020 to 2027, in terms of value.

An extensive analysis of the market provides insights that are expected to allow companies to strategically plan their business moves.

Key market players within the U.S. digital therapeutics market are profiled in this report and their strategies are analyzed thoroughly, which helps in understanding competitive outlook of the market

𝐊𝐞𝐲 𝐅𝐢𝐧𝐝𝐢𝐧𝐠𝐬 𝐎𝐟 𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐲
Software is expected to be one of the most lucrative segments, registering a CAGR of 20.3% during the forecast period.

The business-to-business (B2B) segment accounted for maximum share in the U.S. digital therapeutics market in 2019, and is expected to grow at a CAGR of 18.8% during the forecast period.

Based on business-to-consumers (B2C) segment, the patients segment is expected to project with the highest CAGR throughout the forecast period.
By application, the diabetes segment generates the largest revenue in 2019, and is anticipated to continue this trend during the forecast period.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 𝐩𝐥𝐚𝐲𝐞𝐫𝐬
2MORROW, Inc.
Fitbit, Inc. (Twine Health, Inc.)
Livongo Health, Inc.
Medtronic Plc.
Omada Health, Inc.
Pear Therapeutics, Inc.
Proteus Digital Health, Inc.
Resmed, Inc. (Propeller Health)
Voluntis, Inc.
Welldoc, Inc.

𝐊𝐧𝐨𝐰 𝐌𝐨𝐫𝐞- https://www.alliedmarketresearch.com/us-digital-therapeutics-market-A06701

David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int'l: +1-503-894-6022
UK: +44-845-528-1300Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.